Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company

Pfizer Appoints Citigroup’s Andrew Baum as Executive Vice-President for Strategy and Innovation

Fineline Cube May 7, 2024

Pfizer Inc. (NYSE: PFE) has announced the appointment of Andrew Baum, M.D., to serve as...

Company Drug

EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial

Fineline Cube May 7, 2024

EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert;...

Company

Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability

Fineline Cube May 6, 2024

Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of...

Company Policy / Regulatory

US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies

Fineline Cube May 6, 2024

On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...

Company Drug

Kelun-Biotech’s RET Inhibitor A400 Advances to Phase II Trial with FDA Approval

Fineline Cube May 6, 2024

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, has announced that its...

Company Drug

Everest Medicines’ Nefecon Secures Market Approval for IgAN Treatment in Hong Kong

Fineline Cube May 6, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, announced that it has received market approval...

Company Medical Device

Wondfo Biotech’s WELLlife Test Kit Receives FDA Nod for Home Use in the US

Fineline Cube May 6, 2024

Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has...

Company Medical Device

United Imaging’s uMR Jupiter 5T Becomes First Ultra-High Frequency MRI System to Gain FDA Approval

Fineline Cube May 6, 2024

Shanghai-based medical equipment manufacturer United Imaging Healthcare (UIH, SHA: 688271) has announced that it has...

Company Drug

HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion

Fineline Cube May 6, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...

Company Drug

Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China

Fineline Cube May 6, 2024

Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...

Company Deals Medical Device

Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent

Fineline Cube May 6, 2024

Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered...

Company

Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase

Fineline Cube May 6, 2024

Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the...

Company

Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft

Fineline Cube May 6, 2024

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...

Company Drug

Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO

Fineline Cube May 6, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...

Company Drug

BeiGene’s Anti-PD-1 Therapy Tislelizumab Expands Indication for Gastric Cancer in China

Fineline Cube May 6, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that its anti-PD-1 therapy, tislelizumab, has...

Company Medical Device Policy / Regulatory

China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics

Fineline Cube May 6, 2024

The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...

Company Drug

China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication

Fineline Cube May 6, 2024

Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...

Company Deals

Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing

Fineline Cube May 6, 2024

Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered...

Company

Hainan Poly Pharm’s Manufacturing Units Get GMP Nod From Saudi Food and Drug Authority

Fineline Cube May 6, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, announced that it has...

Policy / Regulatory

GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises

Fineline Cube Apr 30, 2024

The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...

Posts pagination

1 … 322 323 324 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.